Can-Fite BioPharma (CANF) Gets a Buy Rating from H.C. Wainwright

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Can-Fite BioPharma (CANF), with a price target of $5.00. The company’s shares closed last Thursday at $1.80.

According to, Bernardino is a 5-star analyst with an average return of 31.6% and a 38.6% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Viridian Therapeutics, and Tenax Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Can-Fite BioPharma with a $5.00 average price target.

See today’s analyst top recommended stocks >>

Based on Can-Fite BioPharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $211K and GAAP net loss of $2.58 million. In comparison, last year the company earned revenue of $389K and had a GAAP net loss of $3.06 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn’s disease, Osteoathritis, Hepatitis C, and Liver Cancer. Can-Fite BioPharma was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach Tikva, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts